In Vivo is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck & Co. Inc.

www.merck.com

Latest From Merck & Co. Inc.

Health And Wellness On Capitol Hill: Monograph Reform, Wyden On CBD Rule, OTC Daily Contraceptive Access

Energy and Commerce members try again on monograph; Democrats want to ensure OTC oral contraceptive access; Wyden asks for faster CBD rulemaking at FDA; and House passes FDA's FY 2020 funding.

OTC Drugs Dietary Supplements

US FDA May Scrap Clinical Study Report Disclosure For New Drug Approvals

The pilot project former Commissioner Gottlieb championed found only one sponsor interested in participating.
Drug Review FDA

Allergan's Big Deal: A Buyout, Not A Split, Appeases Wary Investors

Allergan was expected to announce soon that it would follow its shareholders' advice and split the company in two, but it's being acquired by AbbVie for $63bn instead, finally giving investors a big boost in their Allergan holdings after years of decline.

Deals Business Strategies

BMS' Bid For Opdivo In First-Line HCC Stymied

Top-line results from a Phase III study testing Opdivo versus Nexavar in first-line liver cancer fail to meet OS target. Bristol points to positive numerical trend, but the results are a setback in the indication.

Life Cycle Management ImmunoOncology
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register